Immunic (IMUX)

What Moves the Stock

1. 01CALLIPER Phase 3 trial interim analyses and primary endpoint readout for vidofludimus calcium in relapsing-remitting MS (expected 2026-2027 based on enrollment timelines)
2. 02ENSURE Phase 3 trial enrollment progress and data readouts for progressive MS indication
3. 03IMU-856 Phase 2 data in ulcerative colitis showing efficacy on endoscopic endpoints and safety profile versus existing JAK inhibitors
4. 04Partnership announcements or licensing deals with major pharmaceutical companies for ex-US rights or specific indications
5. 05Equity financing announcements (dilution risk given negative operating cash flow and limited runway)
6. 06FDA/EMA regulatory feedback on trial designs or breakthrough therapy designation applications
7. 07No current revenue - pre-commercial stage
8. 08Future potential: vidofludimus calcium royalties/sales in MS indication (estimated peak sales $500M-$1B+ if approved)

IMUX Chart

My Notes

• growth/speculative - Attracts biotech-specialized investors, venture capital crossover funds…
• Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (vidofludimus calcium…
• Watch on earnings: CALLIPER trial enrollment completion and event-driven timeline to primary endpoint (annualized relapse rate reduction), Cash and cash equivalents balance versus quarterly operating cash burn trend, IMU-856 Phase 2 endoscopic remission rates in ulcerative colitis versus historical placebo rates (15-20% baseline).